NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

FALSE, Dr. Liau did the interim analysis with the PFS primary endpoint only two years before the trial end.

All the protocol changes came two weeks before the end of the trial. The crossover provision was not part of the protocol except as the required rescue requirement for patients that failed their treatment whether placebo or treatment arm. They also did PFS for the Phase 2 trial and didn't seem to have an issue then and then proposed PFS for the primary endpoint for the P3 trial. It's an NWBO con job.